What Features Predict Poorer Outcomes in Micropapillary Thyroid Carcinoma? A Retrospective Cohort Study
Authors' conclusion
MPTC generally has a good prognosis and responds well to the treatment. Larger tumors (≥7 mm), younger age (<40 years), multifocality, and absence of Hashimoto thyroiditis correlate with a higher American Thyroid Association risk and poorer outcomes.
Study context
- Population
- Patients with PTC with a primary tumour focus ≤10 mm (micropapillary thyroid carcinoma (MPTC)), June 1980 to September 2023; risk stratification and response to treatment by 2015 ATA guidelines
- Participants
- 208 patients
- Outcome
- 2015 ATA risk category
Main finding
As reported in the abstract
- Low risk
- 68.8%
- Intermediate risk
- 29.3%
- High risk
- 1.9%
- Higher risk with larger tumour size (≥7 mm), OR
- 3.196; P value = .001
- Higher risk with multifocality, OR
- 2.431; P value = .004
- Age (protective), OR
- 0.973; P value = .048
- Background Hashimoto thyroiditis (protective), OR
- 0.439; P value = .014
Observational data: associations, not effects.
Further findings
Response to therapy
- Excellent response
- 48.4%
- Structural incomplete response
- 11.2%
- Biochemical incomplete response
- 7.5%
Recurrence
- Recurrence
- 14 (8.18%)
Original publication
What Features Predict Poorer Outcomes in Micropapillary Thyroid Carcinoma? A Retrospective Cohort Study. Endocr Pract. Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →